Suicidality and divalproex sodium: analysis of controlled studies in multiple indications.
BACKGROUND
Recent analyses of antiepileptic drugs have indicated an increase in the risk of suicidality. The objective of this report was to provide clinical information and an independent meta-analysis of divalproex sodium and suicidality events by analyzing data from 13 placebo-controlled studies and 1 low-dose controlled study.


METHODS
Adverse events considered to be possibly suicide related were identified using the Columbia Classification Algorithm of Suicide Assessment (C-CASA) methodology. Indications included epilepsy, bipolar disorder, migraine prophylaxis, impulsive aggression, and dementia. Narratives were produced for every event, and suicidality event ratings were performed by a third party blinded to treatment assignment. Statistical analyses were conducted using methodology similar to that reported by the US Food and Drug Administration (FDA).


RESULTS
Suicidality events were identified in 5 of the 13 placebo-controlled studies. Of the 1,327 (0.83%) subjects taking divalproex sodium, 11 had suicidality events: 2 suicide attempts and 9 suicidal ideation. Of 992 (0.91%) subjects taking placebo, 9 had suicidality events: 1 preparatory act toward suicide, 2 suicide attempts, and 6 suicidal ideation. Across placebo-controlled studies, the overall estimated odds ratio (OR) of suicidal behavior or ideation was 0.72 (95% CI 0.29 to 1.84). The OR for suicidal behavior was 0.37 (95% CI 0.04 to 2.58), and the OR for suicidal ideation was 0.90 (95% CI 0.31 to 2.79).


CONCLUSIONS
In this meta-analysis, divalproex sodium does not appear to increase the risk of suicide-related adverse events relative to placebo in the populations studied. Clinicians should nonetheless remain vigilant in assessing suicidality, not only in patients treated for mental disorders with inherently high suicide risk, but also in patients taking antiepileptic medications.
Abbott, Abbott Park, IL, USA. laura.redden@abbott.com.
Laura
L
Redden
Yili
Y
Pritchett
Weining
W
Robieson
Xenia
X
Kovacs
Mary
M
Garofalo
Katherine
K
Tracy
Mario
M
Saltarelli
MMWR Surveill Summ. 2009 Mar 20;58(1):1-44
19305379
Arch Gen Psychiatry. 2000 May;57(5):481-9
10807488
Arch Gen Psychiatry. 1991 Jan;48(1):62-8
1984763
Neuropsychopharmacology. 2003 Jun;28(6):1186-97
12700713
Epilepsia. 2009 May;50(5):1077-84
19260944
Biometrics. 1985 Mar;41(1):55-68
4005387
Arch Gen Psychiatry. 2009 Dec;66(12):1354-60
19996040
J Affect Disord. 2009 Feb;113(1-2):21-9
18676024
Mol Psychiatry. 2010 Aug;15(8):868-76
19337207
Arch Neurol. 1995 Mar;52(3):281-6
7872882
J Neurosci Nurs. 2007 Dec;39(6):354-60
18186420
Epilepsia. 2009 May;50(5):978-86
19496806
J Child Neurol. 2007 May;22(5 Suppl):61S-70S
17690089
Epilepsia. 2007 Dec;48(12):2336-44
17662062
Epilepsia. 2001 Sep;42(9):1160-8
11580765
Cephalalgia. 1997 Apr;17(2):103-8
9137847
Psychiatr Clin North Am. 2007 Dec;30(4):781-802
17938045
Br J Psychiatry. 1997 Mar;170:205-28
9229027
Bipolar Disord. 2006 Oct;8(5 Pt 2):566-75
17042830
JAMA. 1994 Mar 23-30;271(12):918-24
8120960
J Clin Psychiatry. 2003 Jan;64(1):14-9
12590618
J Psychiatr Pract. 2009 Nov;15(6):433-41
19934717
Neurology. 1997 Jan;48(1):182-8
9008516
Expert Rev Neurother. 2009 Jan;9(1):109-36
19102673
Neurology. 2009 Mar 17;72(11):987-91
19289738
Am J Psychiatry. 1999 Feb;156(2):181-9
9989552
Neurology. 2002 Jun 11;58(11):1652-9
12058094
J Clin Psychiatry. 2006 Oct;67(10):1501-10
17107240
Am J Psychiatry. 2007 Jul;164(7):1035-43
17606655
Acta Neurol Scand. 2009 Feb;119(2):75-80
18759799
Neurology. 1996 Jan;46(1):49-53
8559420
Neurology. 2009 Nov 17;73(20):1710
19917998
Epilepsy Curr. 2008 Mar-Apr;8(2):40-2
18330466
J Clin Psychiatry. 2010 Apr;71(4):426-32
20361904